Tango Therapeutics 第三季度的收益和收入超出了预期，但预计到 2028 年将出现亏损。 Tango Therapeutics beat Q3 earnings and revenue forecasts, but expects losses through 2028.

Tango Therapeutics 于 2025 年 11 月 4 日公布了强劲的第三季度业绩，每股收益为 0.13 美元，收入为 5381 万美元，超出了预期。 Tango Therapeutics reported strong Q3 results on November 4, 2025, beating earnings and revenue estimates with $0.13 EPS and $53.81 million in revenue, surpassing forecasts. 尽管报告积极,分析师还是将2025财政年度损失估计数略微下调到每股0.92美元左右,预计持续损失将持续到2028年。 Despite the positive report, analysts revised FY2025 loss estimates slightly downward to around $0.92 per share, with continued losses projected through 2028. 该公司开发癌症药物TNG908,其市场上限为10.8亿美元,机构所有权为78.99%。 The company, developing cancer drug TNG908, maintains a market cap of $1.08 billion, with institutional ownership at 78.99%. 本季度内部销售额共计2 635万美元。 Insider sales totaled $26.35 million in the quarter. 分析师的评分仍然好坏参半,结果形成了“机动购买”共识,平均价格目标为11美元。 Analyst ratings remain mixed, resulting in a "Moderate Buy" consensus and an average price target of $11.00.